Exploration of drug action on a morphine receptor by methods of enzyme kinetics.

Human serum esterase (pseudocholinesterase) contains a morphine receptor, stimulation of which causes doubling of the rate constant of procaine hydrolysis catalyzed by the esterase. Equations derived from classical enzyme kinetics satisfactorily describe the action of morphine and a number of its derivatives on the enzyme, but 14-hydroxydihydro-6-morphinones are a class apart in having very low apparent affinities for the receptor and very high apparent acceleratory efficacies; further, they anomalously lower the affinity to the receptor of another morphine-related drug present simultaneously. All observations are accounted for by equations derived from the assumption that compounds of this class can also attach to another receptor, stimulation of which likewise doubles the rate constant of the enzymatic hydrolysis and also modifies the affinity of drugs to the first-mentioned receptor.     

Relaxation methods for the determination of drug receptor affinities

According to the occupation theory of drug receptor interaction, the response is a functionf of the number of receptors occupied by drug molecules. Considerable controversy exists regarding assumptions about this function. Without knowledge of the nature of the function, it is not possible to determine directly the rate constants, and hence the affinity constant, in the reaction between the receptor and an agonist drug. Instead, indirect determinations involving the use of antagonists have been employed, limiting the determination of affinity to those agents for which specific antagonists exist. The present paper discusses a method for the direct determination of affinity of an agonist drug. It is a “relaxation method,” i.e., the equilibrium is perturbed and the kinetics of the restoration process are studied. Assuming only thatf is non-decreasing and approximately linear over a limited domain of concentrations, it is shown that the change in response obeys first order kinetics, permitting a determination of the rate constants from the time course of the restoration process.     

A model of antiglucocorticoid action for designing a potent glucocorticoid antagonist

We have previously shown that the biological efficacy of an antiglucocorticoid is directly related to its affinity for the glucocorticoid receptor in whole cells at 37 degrees C. We have also shown that RU 486-receptor complexes differ from other antiglucocorticoid-receptor complexes in so far as their affinity is as high at 37 degrees C in whole cells as at 0 degree C in a cell-free system, whereas a decrease by a factor of 5-10 is observed with the other antagonists. The aim of the present paper was to evaluate the contributions of temperature and cellular integrity (or the biological events linked to temperature and cellular integrity) to the affinity of a steroid for its receptor for the purpose of determining the parameters favorable to high affinity, which is the prerequisite of a potent antagonist. We provide evidence showing that: (1) an increase in temperature has an unfavorable effect on the affinity of a glucocorticoid for its receptor (4-6-fold decrease between 0 and 37 degrees C), (2) RU 486, like an agonist, forms a complex with the cytosolic glucocorticoid receptor, which satisfies the criteria for an "activated" complex under "in vitro activating treatment", (3) these biological post-binding events (either agonistic or otherwise nature), which change the nature of the complexes, contribute to compensating for the negative effect of rising temperatures on their apparent dissociation constant. We conclude that potent antiglucocorticoids must have a chemical structure allowing them to induce biological post-binding events, such as receptor activation, but in an abortive form which thus effectively "traps" the receptor in a non-functional state.     

Computable features required to evaluate the efficacy of drugs and a universal algorithm to find optimally effective drug in a drug complex

Background

The H1N1 pandemic in 2009 and the H5N1 pandemic in 2005 demonstrated that the drugs approved to treat influenza A viruses have low efficacy. This provided a stimulus for new studies of influenza A viruses in the context of the methods used in drug design developed over the past 100 years. Finding new universal drugs is the ultimate goal but its long time horizon is incompatible with emergency situations created by reoccurring influenza outbreaks. Therefore, we propose a computer-aided method for finding efficacious drugs and drug complexes based on the use of the DrugBank database.

Methods

(1) We start by assembling a panel of target proteins. (2) We then assemble a panel of drugs. (3) This is followed by a selection of benchmark binding pockets based on the panel of target proteins and the panel of drugs. (4) We generate a set of computational features, which measure the efficacy of a drug. (5) We propose a universal program to search for drugs and drug complexes. (6) A case study we report here illustrates how to use this universal program for finding an optimal drug and a drug complex for a given target. (7) Validation of the Azirchromycin and Aspirin complex is provided mathematically. (8) Finally, we propose a simple strategy to validate our computational prediction that the Azirchromycin and Aspirin complex should prove clinically effective.

Result

A set of computable features are mined and then based on these features, a universal program for finding the potential drug &drug complexes is proposed. Using this universal program, the Azirchromycin and Aspirin complex is selected and its efficacy is predicted mathematically. For clinical validation of this finding, future work is still required.     

Time-patterned drug administration: insights from a modeling approach

The physiological effects of a drug depend not only on its molecular structure but also on the time-pattern of its administration. One of the main reasons for the importance of temporal patterns in drug action is biological rhythms—particularly those of circadian period. These rhythms affect most physiological functions as well as drug metabolism, clearance, and dynamic processes that may alter drug availability and target cell responsiveness with reference to biological time. We present an overview of the importance of time-patterned signals in physiology focused on the insights provided by a modeling approach. We first discuss examples of pulsatile intercellular communication by hormones such as gonadotropin-releasing hormone, and by cyclic adenosine monophosphate (cAMP) signals in Dictyostelium amoebae. Models based on reversible receptor desensitization account in both cases for the existence of optimal patterns of pulsatile signaling. Turning to circadian rhythms, we examine how models can be used to account for the response of 24h patterns to external stimuli such as light pulses or gene expression, and to predict how to restore the physiological characteristics of altered rhythms. Time-patterned treatments of cancer involve two distinct lines of research. The first, currently evaluated in clinical trials, relies on circadian chronomodulation of anticancer drugs, while the second, mostly based on theoretical studies, involves a resonance phenomenon with the cell-cycle length. We discuss the implications of modeling studies to improve the temporal patterning of drug administration.     

Acute effects of drug administration and withdrawal on the benzodiazepine receptor

Effects of one week of benzodiazepine drug administration on central benzodiazepine receptor binding characteristics were evaluated in a series of experiments in male Sprague-Dawley rats. Administration of short- and intermediate-acting benzodiazepines was observed to increase the number of available receptor binding sites (B_max) without changing affinity of drug for receptor. Furthermore, these changes did not occur after administration and withdrawal of long-acting benzodiazepines. In addition, there appeared to be a relationship between the affinity of the different benzodiazepines for the receptor and the degree of increase in the number of receptor binding sites. The results may help to explain the relationship between withdrawal of certain benzodiazepine drugs and the occurrence of rebound phenomena in clinical situations.     

Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects

While it is currently estimated that 40 to 50% of eukaryotic proteins are phosphorylated, little is known about the frequency and local effects of phosphorylation near pharmaceutical inhibitor binding sites. In this study, we investigated how frequently phosphorylation may affect the binding of drug inhibitors to target proteins. We examined the 453 non‐redundant structures of soluble mammalian drug target proteins bound to inhibitors currently available in the Protein Data Bank (PDB). We cross‐referenced these structures with phosphorylation data available from the PhosphoSitePlus database. Three hundred twenty‐two of 453 (71%) of drug targets have evidence of phosphorylation that has been validated by multiple methods or labs. For 132 of 453 (29%) of those, the phosphorylation site is within 12 Å of the small molecule‐binding site, where it would likely alter small molecule binding affinity. We propose a framework for distinguishing between drug‐phosphorylation site interactions that are likely to alter the efficacy of drugs versus those that are not. In addition we highlight examples of well‐established drug targets, such as estrogen receptor alpha, for which phosphorylation may affect drug affinity and clinical efficacy. Our data suggest that phosphorylation may affect drug binding and efficacy for a significant fraction of drug target proteins. Proteins 2015; 83:25–36. © 2014 Wiley Periodicals, Inc.     

Patterned response to odor in single neurones of goldfish olfactory bulb: influence of odor quality and other stimulus parameters

Responses of 75 single units in the goldfish olfactory bulb were analyzed in detail for their relationship to the time-course of the change in odor concentration during each odor stimulus. Odor stimuli were controlled for rise time, duration, and peak concentration by an apparatus developed for the purpose. This apparatus enabled aqueous odor stimuli to be interposed into a constant water stream without changes in flow rate. The time-course of the concentration change within the olfactory sac was inferred from conductivity measurements at the incurrent and excurrent nostrils. Temporal patterns of firing rate elicited by stimuli with relatively slow rising and falling phases could be quite complex combinations of excitation and suppression. Different temporal patterns were produced by different substances at a single concentration in most units. Statistical measures of the temporal pattern of response for a small number of cells at a given concentration were more characteristic of the stimulus substance than any of three measures of magnitude of response. The temporal patterns change when the peak concentration, duration, and rise time of the stimuli are varied. The nature of these changes suggests that the different patterns are due primarily to the combined influence of two factors: (a) a stimulus whose concentration varies over time and (b) a relationship between concentration and impulse frequency which varies from unit to unit. Some units produce patterns suggestive of influence by neural events of long time constant. The importance of temporal patterns in odor quality and odor intensity coding is discussed.     

A theoretical model study of the comparative effectiveness of atropine and scopolamine action in the central nervous system

The molecular structural factors related to the action of atropine and scopolamine at a common biological receptor, with different apparent potencies, are studied from a theoretical viewpoint. The model molecules representing the two cholinergic antagonists are shown to possess the ability to generate an electrostatic potential field which is compatible with the “interaction pharmacophore” of acetylcholine-like molecules. A common site of action for the two types of drugs is rationalized on this basis. The effect of the differences in the molecular structure of the drugs, on their penetration ability and lipid solubility, is analyzed through the proton affinity of model compounds in the gas phase and in solution. These indicate the nature of the stronger solute-solvent interaction of scopolamine. Results from a comparative calculation of the protonation affinity of the solvated drugs are shown to reproduce the correct ratio of protonated versus free base concentrations for the two molecules, from which the reasons for the lower pKa of scopolamine and higher lipophilicity of atropine (free base) can be understood.     

Stimulus amplification, efficacy, and the operational model. Part II--ternary complex occupancy mechanisms.

To understand how deviations from simple binary occupancy affect measures of efficacy, the generalized stimulus function developed in Part I was used to examine the actions of drugs in systems where occupation of the receptor was modeled using a two-state, ternary complex, or combination of mechanisms.Amplification of drug responses can occur during formation of an active agonist-receptor complex, during generation of the initial stimulus, and during signal transduction. Expressions were derived to characterize the separate contributions of these three phases. Ideally, comparison of relative intrinsic efficacy measures differences in the ability of the agonists to convert active complex into an active stimulus. In practice, differences in the ability of the drugs to form the stimulus-generating complex may also contribute to the efficacy ratio and must be taken into consideration. Failure to adequately account for differences in occupancy can result in overestimation of the efficacy ratio. The magnitude of the difference between true and experimental measures of intrinsic efficacy may be affected by G protein concentration, by the affinity between the G protein and receptor, and (in some models) by the receptor activation constant. Provided that the dissociation constant between the G protein and receptor is of the same order of magnitude as, or lower than the receptor concentration, however, experimental estimates should provide reasonably accurate estimates of the true efficacy ratio.In agreement with previously published experimental data, total G protein level was found capable of influencing agonist maximal response, Emax, and EC50 values in all four ternary complex models. The magnitude of the changes in Emax and EC50 appear to be dependent upon the efficacy of the agonist as well as characteristics of the post-receptor stimulus sequence.Additionally, the concentration-response relations for all four ternary complex models could be reduced to a modified operational format in which the apparent dissociation constant Kapp replaced the true KA, and an apparent operational efficacy, tauapp, replaced tau. tauapp can be estimated experimentally from measurements of the Kapp and EC50, while the operational maximum, Em, may be found from the calculated tauapp and the measured Emax of the response curve. These findings support the use of direct operational model-fitting in a variety of systems, regardless of the mechanisms underlying occupancy.Values of Kapp calculated using the exact formula for [ARG] displayed an anomalous rise or discontinuity where the concentrations of total G protein equaled that of the receptor protein. This discontinuity is not observed in the estimates based on approximations to [ARG], and may explain practical difficulties in evaluating the dissociation constant under these conditions.     

Dopamine receptors in the learning,memory and drug reward circuitry

As primary targets of a variety of abused drugs G-protein-coupled dopamine receptors in the brain play an important role in mediating the various drug-induced alterations in neural and psychological processes thought to underlie the transition from voluntary drug use to habitual and progressively compulsive drug-taking. This review considers the functional involvement of the five major dopamine receptor subtypes in drug reinforcement and reward and discusses the development of addiction as a series of learning transitions from initial goal-directed behaviour to pathological stimulus–response habits in which drug-seeking behaviours are automatically elicited and maintained by cues and stimuli associated with drug rewards.     

Convulsant/depressant site of action at the allosteric benzodiazepine-GABA receptor-ionophore complex

Several classes of centrally acting convulsant, depressant, anticonvulsant and anxiolytic drugs modulate GABAergic transmission. The postsynaptic receptor with which these drugs interact is an allosteric complex with distinct binding sites for GABA, benzodiazepines, picrotoxinin and related compounds. Convulsants which inhibit GABA transmission (except bicuculline) inhibit competitively the binding of dihydropicrotoxinin (DHP) or t-butylbicyclophosphorothionate (TBPT) to the picrotoxinin site and prevent the allosteric enhancing effect of depressant drugs on GABA and benzodiazepine binding. Depressant drugs give a mixed inhibition of TBPT binding. The possible topography of the picrotoxinin site and its relationship to convulsant/depressant drug action at the benzodiazepine-GABA receptor-ionophore complex is discussed.     

Disentangling the nature of the nicotine stimulus

Learning involving interoceptive stimuli likely plays an important role in many diseases and psychopathologies. Within this area, there has been extensive research investigating the interoceptive stimulus effects of abused drugs. In this pursuit, behavioral pharmacologists have taken advantage of what is known about learning processes and adapted the techniques to investigate the behavioral and receptor mechanisms of drug stimuli. Of particular interest is the nicotine stimulus and the use of the two-lever operant drug discrimination task and the Pavlovian drug discriminated goal-tracking task. There is strong concordance between the two methods when using "standard" testing protocols that minimize learning on test days. For example, ABT-418, nornicotine, and varenicline all fully evoked nicotine-appropriate responding. Notably, research from our laboratory with the discriminated goal-tracking task has used an alternative testing protocol. This protocol assesses stimulus substitution based on how well extinction learning using a non-nicotine ligand transfers back to the nicotine stimulus. These findings challenge conclusions based on more "standard" testing procedures (e.g., ABT-418 is not nicotine-like). As a starting point, we propose Thurstone scaling as a quantitative method for more precisely comparing transfer of extinction across doses, experiments, and investigators. We close with a discussion of future research directions and potential implications of the research for understanding interoceptive stimuli.     

Drug release and its relationship with kinetic and thermodynamic parameters of drug sorption onto starch acetate fibers

Drug release and its relationship with kinetic and thermodynamic parameters of drug sorption onto starch acetate (SA) fibers have been studied using Diclofenac, 5‐Fluorouracil (5‐Fu), and Metformin as model drugs. The sorption method is more flexible and can avoid limitations or problems which occur with molten or dissolution methods. To understand drug release of sorption loading, kinetic and apparent thermodynamic parameters, such as diffusion coefficient, activation energy for diffusion, affinity, and sorption enthalpy and entropy, have been investigated. The quantitative relationship between drug release and drug‐loading concentration, affinity, and activation energy for diffusion has been established to predict the initial burst and subsequent release of the drugs. Up to 12% of Diclofenac, based on the weight of SA, can be loaded onto fibers using the sorption method. Drugs with higher activation energy for diffusion, lower diffusion coefficients, and higher affinity for SA fiber, such as Diclofenac, are more suitable for sorption loading. It has also been found that elevated temperatures will achieve higher loading capacity and a more constant release rate. Biotechnol. Bioeng. 2010. 105: 814–822. © 2009 Wiley Periodicals, Inc.     

Determinants of drug effects on punished responding.

The effects of drugs on punished responding depend on interactions among a large number of experimental variables. Among these variables are the drug history of the animal, the dose of the drug administered, the type of stimulus used to punish responding, the intensity and duration of the punishing stimulus, the schedule of presentation of the punishing stimulus, the control rate and pattern of punished responding, the schedule of positive reinforcement maintaining the punished responding, the species of animal, the deprivation state of the animal, the behavioral history of the animal, and the nature of the required response. Although it is not known how all of these variables interact to determine the effect of drugs on punished responding, there is evidence that many of these variables are important as determinants of drug effects. The task facing behavioral pharmacologists studying drug effects on punished responding is to determine under what conditions drugs produce their characteristic effects on punished responding.     

Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile

Evidence from systems biology indicates that promiscuous drugs, i.e. those that act simultaneously at various protein targets, are clinically better in terms of efficacy, than those that act in a more selective fashion. This has generated a new trend in drug development called polypharmacology. However, the rational design of promiscuous compounds is a difficult task, particularly when the drugs are aimed to act at receptors with diverse structure, function and endogenous ligand. In the present work, using docking and molecular dynamics methodologies, we established the most probable binding sites of SB-206553, a drug originally described as a competitive antagonist of serotonin type 2B/2C metabotropic receptors (5-HT_2B/2CRs) and more recently as a positive allosteric modulator of the ionotropic α7 nicotinic acetylcholine receptor (nAChR). To this end, we employed the crystal structures of the 5-HT_2BR and acetylcholine binding protein as templates to build homology models of the 5-HT_2CR and α7 nAChR, respectively. Then, using a statistical algorithm, the similarity between these binding sites was determined. Our analysis showed that the most plausible binding sites for SB-206553 at 5-HT₂Rs and α7 nAChR are remarkably similar, both in size and chemical nature of the amino acid residues lining these pockets, thus providing a rationale to explain its affinity towards both receptor types. Finally, using a computational tool for multiple binding site alignment, we determined a consensus binding site, which should be useful for the rational design of novel compounds acting simultaneously at these two types of highly different protein targets.     

Flux detectors versus concentration detectors: two types of chemoreceptors

Dose-response curves relating the external stimulus concentration to receptor occupancy differ in two types of chemoreceptor organs. In 'concentration detectors' the receptor molecules at the receptor cell membrane are directly exposed to the external stimulus concentration; these organs exhibit the well-known hyperbolic dose-response relationship reflecting the association-dissociation of stimulus and receptor molecules. In contrast, 'flux detectors' accumulate the stimulus molecules in a perireceptor compartment. In flux detectors, deactivation of stimulus molecules may be in balance with arrival, as a prerequisite for producing a constant effective stimulus concentration at constant adsorptive flux of stimulus molecules. In a simple model of a flux detector in which receptor molecules themselves catalyze the deactivation, the dose-response relationship is linear. It reflects the rate of stimulus deactivation. If the deactivation is catalyzed by a separate enzyme, the dose-response relationship can be close to hyperbolic, or linear. In all cases, the receptor molecules are maximally occupied if the adsorptive flux equals or exceeds the maximum rate of stimulus deactivation. The time course of the receptor potential recorded from moths' pheromone receptors depends on the odor compound, which suggests that a peripheral process, possibly the stimulus deactivation, is the slowest, rate-limiting process of the transduction cascade. Further evidence comes from experiments with stimuli oversaturating the mechanism responsible for the decline of the receptor potential.      

Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine

4'-(9-acridinylamino) methanesulfon-m-anisidide (amsacrine or AMSA), an antitumor drug which has been tested in clinical trials, is known to bind to DNA by the intercalation of its 9-amino acridine moiety between DNA base pairs. Like AMSA, a peptidic derivative of 4-(9-acridinylamino) aniline, 4-(9-acridinylamino)-N-(lysylglycyl) aniline (ALGA) binds to DNA by intercalation and its affinity for the target was found to be higher than the parent drug. The antitumor effect of AMSA and ALGA has been monitored by drug exposure assays on EMT 6 cells. AMSA showed a slightly higher cytotoxic activity. The cell cycle effects of both drugs were studied using flow cytofluorimetry; an accumulation of cells in the S phase followed by a cycle arrest in the G2 phase, characteristic of intercalating drugs, was observed.     

In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action

In addition to being dopamine antagonists, all antipsychotic drugs are potent antagonists of alpha-1 noradrenergic receptors. Nevertheless, the contribution of alpha blockade to the clinical therapeutic effects of the antipsychotic drugs has never attracted extensive study. In particular, the relative alpha-1 noradrenergic antagonist potency of antipsychotic drugs has rarely been determined in vivo during extended treatment, although such treatment would provide a better model of clinical drug effects than the determination of potencies in in vitro systems, such as assays of competition for binding sites in tissue homogenates, as is most often done. To estimate the physiological efficacy of antipsychotic drugs as dopamine and alpha adrenergic antagonists, we treated rats for four weeks with daily IP injections of the following antipsychotic drugs: Fluphenazine, 1 mg/kg; haloperidol, 1 mg/kg; chlorpromazine, 25 mg/kg; thioridazine, 25 mg/kg; and clozapine, 25 mg/kg. Effective antagonism should lead to an increase in density of the relevant receptors. After two drug-free days, rats were sacrificed and the affinity and density of dopamine D2 and alpha-1 noradrenergic receptors were determined in striatum and brain exclusive of striatum, respectively. Alpha 1 noradrenergic receptor density but not dopamine receptor density was increased after all treatments. Thus, preliminary experiments with this in vivo model suggest that all antipsychotic drugs are effective antagonists at alpha 1 noradrenergic receptors, while not all are effective antagonists at dopamine D2 receptors.     

Studies on the mechanism of action of peptide attacking smooth muscle. II. Differentiation of biologic activity of tachykinins in affinity and intrinsic efficacy]

Under the condition of receptor blockade produced by continuous presence of an agonist in the organ bath, it was attempted to determine the dissociation constants for C-terminal partial sequences of the substance P at an isolated guinea pig ileum, by analogy with the method involving irreversible antagonists, and to compare them with the biological activity at the guinea pig ileum and the rat colon (ED50 values). Differentiation of the biological activity at the guinea pig ileum into affinity and "intrinsic efficacy" allows one to explain quantitative differences in determining the biological value on both isolated organs, and to reveal the contribution of the individual amino acids to affinity and "intrinsic efficacy".